195 related articles for article (PubMed ID: 10828648)
1. New hypointense lesions on MRI in relapsing-remitting multiple sclerosis patients.
Wagner S; Adams H; Sobel DF; Slivka LS; Sipe JC; Romine JS; Koziol JA
Eur Neurol; 2000; 43(4):194-200. PubMed ID: 10828648
[TBL] [Abstract][Full Text] [Related]
2. Asymmetries in the spatial distributions of enhancing lesions and black holes in relapsing-remitting MS.
Koziol JA; Wagner S; Sobel DF; Feng AC; Adams HP
J Clin Neurosci; 2005 Nov; 12(8):895-901. PubMed ID: 16249086
[TBL] [Abstract][Full Text] [Related]
3. T1- Thresholds in Black Holes Increase Clinical-Radiological Correlation in Multiple Sclerosis Patients.
Thaler C; Faizy T; Sedlacik J; Holst B; Stellmann JP; Young KL; Heesen C; Fiehler J; Siemonsen S
PLoS One; 2015; 10(12):e0144693. PubMed ID: 26659852
[TBL] [Abstract][Full Text] [Related]
4. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Giovannoni G; Soelberg Sorensen P; Cook S; Rammohan K; Rieckmann P; Comi G; Dangond F; Adeniji AK; Vermersch P
Mult Scler; 2018 Oct; 24(12):1594-1604. PubMed ID: 28870107
[TBL] [Abstract][Full Text] [Related]
6. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.
van Walderveen MA; Lycklama A Nijeholt GJ; Adèr HJ; Jongen PJ; Polman CH; Castelijns JA; Barkhof F
Arch Neurol; 2001 Jan; 58(1):76-81. PubMed ID: 11176939
[TBL] [Abstract][Full Text] [Related]
7. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Radue EW; Sprenger T; Vollmer T; Giovannoni G; Gold R; Havrdova E; Selmaj K; Stefoski D; You X; Elkins J
Eur J Neurol; 2016 Feb; 23(2):412-5. PubMed ID: 26806217
[TBL] [Abstract][Full Text] [Related]
8. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
9. Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients.
Adams HP; Wagner S; Sobel DF; Slivka LS; Sipe JC; Romine JS; Beutler E; Koziol JA
Eur Neurol; 1999 Jul; 42(1):52-63. PubMed ID: 10394049
[TBL] [Abstract][Full Text] [Related]
10. The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis.
Barkhof F; de Jong R; Sfikas N; de Vera A; Francis G; Cohen J;
Mult Scler; 2014 Nov; 20(13):1704-13. PubMed ID: 24812043
[TBL] [Abstract][Full Text] [Related]
11. Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis.
Oreja-Guevara C; Charil A; Caputo D; Cavarretta R; Sormani MP; Filippi M
Arch Neurol; 2006 May; 63(5):736-40. PubMed ID: 16682543
[TBL] [Abstract][Full Text] [Related]
12. Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis.
Rovaris M; Comi G; Ladkani D; Wolinsky JS; Filippi M;
AJNR Am J Neuroradiol; 2003 Jan; 24(1):75-81. PubMed ID: 12533330
[TBL] [Abstract][Full Text] [Related]
13. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Giovannoni G; Comi G; Cook S; Rammohan K; Rieckmann P; Soelberg Sørensen P; Vermersch P; Chang P; Hamlett A; Musch B; Greenberg SJ;
N Engl J Med; 2010 Feb; 362(5):416-26. PubMed ID: 20089960
[TBL] [Abstract][Full Text] [Related]
14. Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis.
Novakovic AM; Krekels EH; Munafo A; Ueckert S; Karlsson MO
AAPS J; 2017 Jan; 19(1):172-179. PubMed ID: 27634384
[TBL] [Abstract][Full Text] [Related]
15. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Ali S; Paracha N; Cook S; Giovannoni G; Comi G; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Greenberg S; Scott DA; Joyeux A;
Clin Drug Investig; 2012 Jan; 32(1):15-27. PubMed ID: 22017519
[TBL] [Abstract][Full Text] [Related]
16. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
17. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
Barkhof F; Hulst HE; Drulovic J; Uitdehaag BM; Matsuda K; Landin R;
Neurology; 2010 Mar; 74(13):1033-40. PubMed ID: 20200338
[TBL] [Abstract][Full Text] [Related]
18. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Comi G; Filippi M; Wolinsky JS
Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
[TBL] [Abstract][Full Text] [Related]
19. An update on cladribine for relapsing-remitting multiple sclerosis.
Holmøy T; Torkildsen Ø; Myhr KM
Expert Opin Pharmacother; 2017 Oct; 18(15):1627-1635. PubMed ID: 28858531
[TBL] [Abstract][Full Text] [Related]
20. Cladribine in aggressive forms of multiple sclerosis.
Martinez-Rodriguez JE; Cadavid D; Wolansky LJ; Pliner L; Cook SD
Eur J Neurol; 2007 Jun; 14(6):686-9. PubMed ID: 17539951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
